Guardant Health has secured US Food and Drug Administration (FDA) approval for its next generation liquid biopsy panel for informing cancer treatment decisions, combining genomic and epigenomic profiling to reveal further insight for cancer patients via a blood draw.

Guardant360 Liquid’s approval covers its application as a companion diagnostic (CDx) for multiple therapies in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), and for targeted therapy in advanced breast cancer patients with oestrogen receptor 1 (ESR1) mutations. The seven indications that its previous iteration, Guardant360 CDx, held transfer over to the new panel.

According to Guardant, Guardant360 Liquid CDx’s integration of genomic and epigenomic insights means the panel can assess a much wider genomic footprint than the company’s previously approved Guardant360 diagnostic.